Get the Stockscreener App
4.37
0.68%
-0.03
Pre-market:
4.70
0.33
+7.55%
Clene Inc stock is traded at $4.37, with a volume of 33,572.
It is down -0.68% in the last 24 hours and down -4.17% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
See More
Previous Close:
$4.40
Open:
$4.47
24h Volume:
33,572
Relative Volume:
0.52
Market Cap:
$36.38M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-0.9798
EPS:
-4.46
Net Cash Flow:
$-27.47M
1W Performance:
-3.53%
1M Performance:
-4.17%
6M Performance:
-35.16%
1Y Performance:
-50.30%
1-Day Range:
$4.30
$4.59
1-Week Range:
$4.25
$4.6594
52-Week Range:
$3.8181
$9.20
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
4.37 | 36.38M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
30.19 | 36.66B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
59.85 | 32.99B | 19.90B | 2.60B | 2.80B | 4.60 |
|
K
Kellanova
|
82.30 | 28.11B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
80.73 | 21.65B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
29.49 | 16.22B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
HC Wainwright Reaffirms “Buy” Rating for Clene (NASDAQ:CLNN) - Defense World
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
H.C. Wainwright maintains Clene stock Buy rating, $31 target - Investing.com India
H.C. Wainwright maintains Clene stock Buy rating, $31 target By Investing.com - Investing.com South Africa
Clene reports ALS treatment survival benefit in trial By Investing.com - Investing.com Australia
Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients - Streetwise Reports
Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference - Financial Content
Clene reports ALS treatment survival benefit in trial - Investing.com India
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment - The Manila Times
Breakthrough: New ALS Drug Extends Patient Survival by 198 Days in Major Clinical Study - StockTitan
Clene (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit - Barchart
Clene to Present at the 37TH Annual Roth Conference - The Manila Times
Clene Inc. to Participate in 37th Annual Roth Conference with Virtual Fireside Chat and Investor Meetings - Nasdaq
Can Clene's Neurodegenerative Disease Treatments Transform ALS and MS Care? - StockTitan
Investornewsbreaks Clene Inc. (NASDAQ: CLNN) To Participate In 37Th Annual Roth Conference - MENAFN.COM
Clene (CLNN) to Release Quarterly Earnings on Wednesday - Defense World
Clene (NASDAQ: CLNN) CEO And CFO To Present At Investor Summit Virtual On March 11 - Barchart
New analyses in ALS planned to aid CNM-Au8’s accelerated approval - ALS News Today
What Will Clene Executives Reveal at the Upcoming Investor Summit? - StockTitan
Clene (NASDAQ:CLNN) Earns “Buy” Rating from HC Wainwright - Defense World
Clene (NASDAQ:CLNN) Earns Buy Rating from D. Boral Capital - Defense World
H.C. Wainwright maintains $31 target on Clene stock with Buy rating - Investing.com Canada
Clene to analyze ALS patient data for FDA drug application By Investing.com - Investing.com Canada
Clene to analyze ALS patient data for FDA drug application - Investing.com India
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction - The Manila Times
Can Clene's New Partnership Fast-Track Its ALS Drug Through FDA Hurdles? - StockTitan
Silicon Valley - Financial Content
Clene Inc. (NASDAQ:CLNN) Short Interest Up 10.3% in January - Defense World
Nanotechnology Stocks To ResearchFebruary 13th - MarketBeat
Could a New Drug Help Restore Vision? Early Findings in Myelin Repair - Securities.io
7 Best Nanotech Penny Stocks to Invest In - Insider Monkey
Is Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In? - Insider Monkey
Nanotechnology Stocks To Watch TodayFebruary 09th - MarketBeat
Promising Nanotechnology Stocks To Follow TodayFebruary 11th - MarketBeat
Nanotechnology Stocks To Keep An Eye OnFebruary 08th - MarketBeat
Critical LDAP Vulnerability Puts Windows Systems at Risk - Experts' club
Best Nanotechnology Stocks To Watch NowFebruary 07th - MarketBeat
Promising Nanotechnology Stocks To Watch TodayFebruary 06th - MarketBeat
Nanotechnology Stocks To Follow NowFebruary 05th - MarketBeat
Promising Nanotechnology Stocks To Watch Today – February 06th - Armenian Reporter
Clene Inc. secures additional NIH grant funds for ALS therapy - MSN
Promising Nanotechnology Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Best Nanotechnology Stocks To Follow TodayJanuary 30th - MarketBeat
Clene Inc. secures additional NIH grant funds for ALS therapy By Investing.com - Investing.com UK
Beyond Meat (BYND) Stock Plummets Amidst Market Volatility - GuruFocus.com
NATR Stock Surges Over 5% Amid Strong Financial Performance - GuruFocus.com
Clene files to sell 1.15M shares of common stock by selling shareholders - MSN
Clene (CLNN) Stock Price, News & Analysis - MarketBeat
3 US Growth Stocks With High Insider Ownership And Revenue Growth Up To 25% - Yahoo Finance
IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS - Nasdaq
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
| General Resonance LLC | 10% Owner |
Apr 30 '24 |
Sale |
0.42 |
13,000 |
5,416 |
15,326,712 |
| General Resonance LLC | 10% Owner |
May 01 '24 |
Sale |
0.40 |
13,000 |
5,148 |
15,313,712 |
| General Resonance LLC | 10% Owner |
Apr 24 '24 |
Sale |
0.33 |
10,000 |
3,278 |
15,349,712 |
| General Resonance LLC | 10% Owner |
Apr 09 '24 |
Sale |
0.39 |
22,500 |
8,674 |
15,428,212 |
2.72%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):